Ryuge Shinichiro, Jiang Shi-Xu, Wada Mayuko, Katono Ken, Iwasaki Maiko, Takakura Akira, Otani Sakiko, Kimura Yuka, Fukui Tomoya, Yokoba Masanori, Kubota Masaru, Katagiri Masato, Hayakawa Kazusige, Masuda Noriyuki
Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa, Japan.
Drug Des Devel Ther. 2009 Sep 21;3:213-7. doi: 10.2147/dddt.s6423.
Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment regimen may be beneficial for patients with advanced LCNEC.
大细胞神经内分泌癌(LCNEC)是一种相对少见的非小细胞肺癌变体。由于LCNEC的生物学特性与小细胞肺癌相似,LCNEC通常采用用于小细胞肺癌的化疗方案进行治疗。然而,治疗结果通常很不理想。在此,我们报告一名患有LCNEC(脑转移)的患者。全脑照射后,他接受了氨柔比星和伊立替康联合化疗,并且已经无复发两年。这种治疗方案可能对晚期LCNEC患者有益。